Arecor Therapeutics PLC has announced the appointment of David Ellam as its interim chief financial officer, effective immediately. This appointment comes following the resignation of Susan Lowther, the company's first CFO, in April. The CEO, Sarah Howell, expressed confidence in Ellam's extensive finance and life sciences knowledge, emphasizing the value he will bring in supporting the company's strategic initiatives and driving shareholder value.
Who to call at Arecor Therapeutics PLC, and when
A new leader at Arecor Therapeutics PLC brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Arecor Therapeutics PLC raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Arecor Therapeutics PLC, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Arecor Therapeutics PLC
Location
Cambridge, England, United Kingdom
About
Arecor Therapeutics PLC is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arecor Therapeutics PLC changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma